Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advance or Metastatic Pancreatic Cancer
Conditions: Locally Advanced Pancreatic Adenocarcinoma; Metastatic Pancreatic Adenocarcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Adenocarcinoma Interventions: Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Procedure: Endoscopic Ultrasound; Drug: Fluorouracil; Drug: Irinotecan; Drug: Leucovorin; Procedure: Lymph Node Biopsy; Procedure: Magnetic Resonance Imaging; Drug: Oxaliplatin; Biological: Pembrolizumab; Drug: Photodynamic Therapy; Procedure: Positron Emission Tomography; Other: Questi...
Source: ClinicalTrials.gov - April 24, 2024 Category: Research Source Type: clinical trials
Risk Factors of Postoperative Complications and Survival Rate in Pancreatic Ductal Adenocarcinoma Patients
Conditions: Pancreatic Cancer Interventions: Other: no intervention Sponsors: Jinling Hospital, China Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 23, 2024 Category: Research Source Type: clinical trials
Establishing a Tumor Registry of Patients With Mesonephric-like Adenocarcinoma (MLA)
Conditions: Mesonephric-like Adenocarcinoma Sponsors: M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 22, 2024 Category: Research Source Type: clinical trials
The Prognostic Impact of Surufatinib for the Treatment of Advanced Pancreatic Ductal Adenocarcinoma
Conditions: Pancreatic Cancer Interventions: Drug: Surufatinib combine immune checkpoint inhibitor; Drug: AG/FOLFIRINOX Sponsors: Luo Cong Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 22, 2024 Category: Research Source Type: clinical trials
Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases
Conditions: Her2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastasis Interventions: Drug: Neratinib maleate in combination with capecitabine Sponsors: Convalife (Shanghai) Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
A Study Collecting Health Information to Understand and Prevent Gastric Cancer
Conditions: Gastric Atrophy; Gastric Intestinal Metaplasia; Dysplasia; Gastric Adenocarcinoma; Gastric Cancer Interventions: Behavioral: Questionnaire Sponsors: Memorial Sloan Kettering Cancer Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2024 Category: Research Source Type: clinical trials
Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment Prostate Cancer
Conditions: Oligometastatic Prostate Carcinoma; Prostate Adenocarcinoma Interventions: Drug: Abiraterone Acetate; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Biological: Gonadotropin-releasing Hormone Analog; Procedure: Magnetic Resonance Imaging; Procedure: Positron Emission Tomography; Other: Questionnaire Administration; Radiation: Radiation Therapy Sponsors: Mayo Clinic Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2024 Category: Research Source Type: clinical trials
Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors
Conditions: Clinical Stage III Gastric Cancer AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Locally Advanced Gastric Carcinoma; Locally Advanced Gastroesophageal Junction Adenocarcinoma; Locally Advanced Malignant Solid Neoplasm; Metastatic Gastric Carcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Metastatic Malignant Solid Neoplasm; Unresectable Gastric Carcinoma; Unresectable Gastroesophageal Junction Adenocarcinoma; Unresectable Malignant Solid Neoplasm Interventions...
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Comparison of Outcomes of Multiple Platforms for Assisted Robotic - Gastrectomy
Conditions: Gastric Cancer; Gastrointestinal Cancer; Neoplasms; Gastric Diffuse Adenocarcinoma; Gastric Neoplasm; Stomach Adenocarcinoma Interventions: Device: DaVinci ® Surgical System; Device: Hugo™ RAS System; Device: Versius® Robotic Surgery System Sponsors: Azienda Ospedaliera Universitaria Integrata Verona Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer
Conditions: Pancreatic Cancer; Pancreatic Cancer Non-resectable; Pancreatic Ductal Adenocarcinoma, PDAC Interventions: Drug: surufatinib combined with gemcitabine plus nab-paclitaxel Sponsors: Wuhan Union Hospital, China Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2024 Category: Research Source Type: clinical trials
EchoTip AcuCore Post-Market Clinical Study
Conditions: Adenocarcinoma; Neuroendocrine Tumors; Hepatocellular Carcinoma; Cholangiocarcinoma; Malignant Lymphoma; Metastasis; Chronic Pancreatitis; Autoimmune Pancreatitis Interventions: Device: EchoTip AcuCore Sponsors: Cook Research Incorporated Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
A Study to Evaluate MK-2870 in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
Conditions: Gastroesophageal Cancer Interventions: Biological: MK-2870; Drug: Trifluridine-Tipiracil; Drug: Irinotecan; Drug: Paclitaxel; Drug: Docetaxel Sponsors: Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.
Conditions: Locally Advanced or Metastatic GC and GCJ Adenocarcinoma Interventions: Drug: LM-302; Drug: Apatinib; Drug: Irinotecan Sponsors: LaNova Medicines Zhejiang Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 8, 2024 Category: Research Source Type: clinical trials
Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells for Gastric/Gastroesophageal Junction Adenocarcinoma
Conditions: Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma Interventions: Drug: Claudin18.2-Targeted Chimeric Antigen Receptor T Cell Injection Sponsors: Peking University; Gracell Biopharmaceuticals, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 8, 2024 Category: Research Source Type: clinical trials
A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.
Conditions: Gastroesophageal Junction Adenocarcinoma; Liver Cancer Stage IV; Biliary Tract Cancer; Pancreatic Adenocarcinoma; Colorectal Cancer; Gastric Cancer Interventions: Radiation: Hypofractionated radiotherapy/SBRT （5-8 Gy/fx，3-5 fx）; Drug: Anti-PD-1 monoclonal antibody; Drug: Oxaliplatin and Capecitabine; Drug: Anti-VEGF 15mg/kg; Drug: Anti-VEGF 7.5mg/kg; Drug: Gemcitabine and Cisplatin; Drug: Gemcitabine and Albumin paclitaxel Sponsors: Zhejiang Cancer Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2024 Category: Research Source Type: clinical trials
